- Honduran helicopter crash kills six, including president's sister
- Brazil's Workers Party formalizes support for ex-president Lula
- Foreign minister warns UK cannot become 'vassal state' of EU
- More than half of Britons now want to stay in EU - poll
- An update on winners and losers on the U.S. tax scorecard
- Uber accused of espionage, hacking and bribery in bombshell letter
- Christian Bale and more to salute CNN Heroes
- Destiny 2 Xur Location Guide: Where Is Xur, What Is He Selling? (December 15-18)
- More than half of Britons now want to stay in EU: poll
- Mudslide in southern Chile kills three; 15 others missing
- Odebrecht says dealings with Peru president were legitimate
- U.N. council mulls call for U.S. Jerusalem decision to be withdrawn
- Tillerson confronts North Korea at UN
- Elysee plays down opulence of Macron birthday at Loire chateau
- Argentina fires head of navy over submarine tragedy
- Egyptian presidential hopeful apologizes to arrested supporters
- Argentina fires head of navy after submarine tragedy
- Canadian police probe mysterious deaths of billionaire pharma couple
- Nazareth Christmas celebrations will be held as normal: mayor
- Libyan coast guard rescues more than 250 migrants trying to reach Ital
Brazil recommends restrictions on Sanofi dengue vaccine
BRASILIA (Reuters) - The Brazilian government said on Monday it has suggested restrictions on the use of a dengue vaccine that has been suspended elsewhere after French drug company Sanofi SA said it could worsen the disease in some cases.
Brazil’s healthcare regulator Anvisa said it is now recommending that people who have never been infected with dengue not take the vaccine, which was approved for use in Brazil at the end of 2015. The Brazilian government has not suspended the drug entirely, although the Philippine government has.
Anvisa did not immediately respond to a request for comment. It was not immediately known many people have taken the vaccine, if it was part of any government immunization program or if any illnesses or deaths linked to the drug have been reported to the government.
A spokesman for Sanofi in Paris was not immediately available for comment.
Reporting by Anthony Boadle in Brasilia and Brad Brooks in Sao Paulo; Editing by Jeffrey Benkoe
Our Standards:The Thomson Reuters Trust Principles.